Cybin (NASDAQ:HELP) Trading 9.7% Higher Following Insider Buying Activity

Cybin Inc. (NASDAQ:HELP)’s share price shot up 9.7% during mid-day trading on Monday following insider buying activity. The stock traded as high as $13.38 and last traded at $13.5660. Approximately 487,342 shares traded hands during mid-day trading, a decline of 61% from the average daily volume of 1,235,494 shares. The stock had previously closed at $12.37.

Specifically, CEO Michael Halstead purchased 100,000 shares of the firm’s stock in a transaction dated Monday, September 21st. The shares were acquired at an average cost of $13.47 per share, with a total value of $1,347,000.00. Following the completion of the purchase, the chief executive officer directly owned 168,568 shares of the company’s stock, valued at $2,270,610.96. This trade represents a 145.84% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Wells Fargo & Company began coverage on Cybin in a research note on Monday, July 27th. They set an “overweight” rating and a $16.00 price objective for the company. Wall Street Zen upgraded Cybin from a “strong sell” rating to a “sell” rating in a report on Saturday, August 29th. Barclays assumed coverage on shares of Cybin in a research report on Friday, September 18th. They set an “overweight” rating and a $35.00 price target on the stock. Finally, TD Cowen lifted their target price on Cybin from $8.00 to $62.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. Six research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $46.33.

Cybin News Summary

Here are the key news stories impacting Cybin this week:

• Positive Sentiment: CEO Michael Halstead purchased 100,000 shares at an average price of $13.47, investing approximately $1.35 million. The transaction increased his direct holdings by about 146% and may be interpreted as a strong vote of confidence in the company’s outlook. SEC insider transaction filing
• Positive Sentiment: Cybin presented four new analyses of HLP003, its investigational oral deuterated psilocin analog, at Psych Congress 2026. The analyses further characterized the drug and its Phase 3 PARADIGM program for adjunctive treatment of major depressive disorder, potentially increasing investor confidence in the development pipeline. HLP003 Psych Congress announcement
• Positive Sentiment: Shareholders overwhelmingly approved the appointment of Zeifmans LLP as auditor, an eight-member board and all director nominees. Strong approval of the resolutions supports management’s governance plans as the company advances its clinical programs. Annual and special meeting results
• Positive Sentiment: The company will legally change its name from Cybin Inc. to Helus Pharma Inc. on October 1, reflecting its goal of transitioning from a discovery and development company into a commercial-ready pharmaceutical business. Management is also scheduled to discuss its serotonergic pipeline at the TD Cowen Neuropsychiatry Summit on September 23. TD Cowen summit announcement
• Neutral Sentiment: Analyst price targets remain widely dispersed, with recent targets ranging from $8 to $70. The bullish targets could improve sentiment, but the wide range highlights substantial uncertainty about clinical and commercial execution.
• Negative Sentiment: HLP003 and the broader serotonergic pipeline remain investigational. Regulatory approval, successful Phase 3 results and commercialization are not guaranteed, and the company continues to face development costs and potential losses.

Cybin Trading Up 0.4%

The company has a 50-day moving average of $10.95 and a 200-day moving average of $7.17. The firm has a market capitalization of $1.08 billion, a P/E ratio of -4.54 and a beta of 0.63.

Cybin (NASDAQ:HELP) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.91) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.11). Research analysts predict that Cybin Inc. will post -2.95 EPS for the current year.

Institutional Trading of Cybin

A hedge fund recently bought a new stake in Cybin stock. Pale Fire Capital SE purchased a new stake in shares of Cybin Inc. (NASDAQ:HELP) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 153,505 shares of the company’s stock, valued at approximately $1,015,000. Pale Fire Capital SE owned 0.21% of Cybin as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 17.94% of the company’s stock.

About Cybin

Cybin Inc is a clinical-stage biopharmaceutical company focused on developing psychedelic-based therapeutics for the treatment of mental health conditions. The company combines drug discovery, clinical development and proprietary formulation technologies to design potentially more efficient and scalable psychedelic treatments.

Cybin’s development programs have included CYB003, an investigational deuterated psilocybin analog being studied for major depressive disorder, and CYB004, an investigational deuterated DMT molecule being evaluated for generalized anxiety disorder and other mental health indications.